Thomas John Dietz, Director at Eiger BioPharmaceuticals, Inc. (EIGR), bought 2,500 shares at $8.48 ($21K) on 2021-04-09, disclosed to the SEC on 2021-04-12.
Open-market purchase of $21k EIGR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.48 | 1,500 | $13K | 59.9% |
| 2 | $8.50 | 1,000 | $9K | 40.1% |
| Total | $8.49 avg | 2,500 | $21K | 100% |
| Filing → |
| EIGR | SELL | 2022-12-27 | $26K | — | Filing → |
| EIGR | BUY | 2020-03-17 | $5K | — | Filing → |
| EIGR | BUY | 2020-01-13 | $56K | — | Filing → |